39 results on '"Bergua, Juan-Miguel"'
Search Results
2. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
- Author
-
Ribera, Josep-Maria, Morgades, Mireia, Ciudad, Juana, Montesinos, Pau, Esteve, Jordi, Genescà, Eulàlia, Barba, Pere, Ribera, Jordi, García-Cadenas, Irene, Moreno, María José, Martínez-Carballeira, Daniel, Torrent, Anna, Martínez-Sánchez, Pilar, Monsalvo, Silvia, Gil, Cristina, Tormo, Mar, Artola, María Teresa, Cervera, Marta, González-Campos, José, Rodríguez, Carlos, Bermúdez, Arancha, Novo, Andrés, Soria, Beatriz, Coll, Rosa, Amigo, María-Luz, López-Martínez, Aurelio, Fernández-Martín, Rosa, Serrano, Josefina, Mercadal, Santiago, Cladera, Antònia, Giménez-Conca, Alberto, Peñarrubia, María-Jesús, Abella, Eugènia, Vall-llovera, Ferran, Hernández-Rivas, Jesús-María, Garcia-Guiñon, Antoni, Bergua, Juan-Miguel, de Rueda, Beatriz, Sánchez-Sánchez, María-José, Serrano, Alfons, Calbacho, María, Alonso, Natalia, Méndez-Sánchez, Jose-Ángel, García-Boyero, Raimundo, Olivares, Matxalen, Barrena, Susana, Zamora, Lurdes, Granada, Isabel, Lhermitte, Ludovic, Feliu, Evarist, and Orfao, Alberto
- Published
- 2021
- Full Text
- View/download PDF
3. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
- Author
-
Simoes, Catia, Paiva, Bruno, Martínez-Cuadrón, David, Bergua, Juan-Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez, Jose-Luis, Vidriales, Maria-Belen, Labrador, Jorge, Falantes, Jose-Francisco, Sayas, María-José, Ayala, Rosa, Martinez-Lopez, Joaquin, Villar, Sara, Calasanz, Maria-Jose, Prosper, Felipe, San-Miguel, Jesús F., Sanz, Miguel Ángel, and Montesinos, Pau
- Published
- 2021
- Full Text
- View/download PDF
4. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
- Author
-
Martínez Sánchez, María P., Megías-Vericat, Juan Eduardo, Rodríguez-Veiga, Rebeca, Vives, Susana, Bergua, Juan Miguel, Torrent, Anna, Suárez-Varela, Sara, Boluda, Blanca, Martínez-López, Joaquín, Cano-Ferri, Isabel, Acuña-Cruz, Evelyn, Torres-Miñana, Laura, Martín-Herreros, Beatriz, Serrano, Alfons, Sempere, Amparo, Barragán, Eva, Sargas, Claudia, Sanz, Miguel, Martínez-Cuadrón, David, and Montesinos, Pau
- Published
- 2021
- Full Text
- View/download PDF
5. Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy
- Author
-
Ribera, Josep-Maria, García, Olga, Chapchap, Eduardo Cerello, Gil, Cristina, González-Campos, José, Barba, Pere, Amigo, María-Luz, Moreno, María-José, Lavilla, Esperanza, Alonso, Natalia, Bergua, Juan-Miguel, Tormo, Mar, Ribera, Jordi, Sierra, Magdalena, Martínez-Carballeira, Daniel, Mercadal, Santiago, Hernández-Rivas, Jesús-María, Vall-llovera, Ferran, Genescà, Eulàlia, Cladera, Antònia, Novo, Andrés, Abella, Eugènia, García-Cadenas, Irene, Monteserín, Carmen, Bermúdez, Arancha, Piernas, Sonia, Montesinos, Pau, López, Jose-Luis, García-Guiñón, Antoni, Serrano, Alfons, Martínez, María-Pilar, Olivares, Matxalen, López, Aurelio, and Serrano, Josefina
- Published
- 2020
- Full Text
- View/download PDF
6. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
- Author
-
Rojas, F., Longoni, H., Milone, G., Fernández, I., Conciencia, Clínica, Ramirez, R., Canepa, C., Saba, S., Balladares, G., Ventiurini, C., Mariano, R., Negri, P., Prates, M.V., Milone, J., Fazio, P., Gelemur, M., Ciarlo, S., Bezares, F., López, L., García, J. J, Giunta, M., Kruss, M., Lafalse, D., Marquesoni, E., Casale, M.F., Gimenez, A., Brulc, E.B., Perusini, M.A., Palmer, L., Correa, M.E., Jaramillo, F.J., Rosales, J., Sossa, C., Herrera, J.C., Arango, M., Holojda, J., Golos, A., Ejduk, A., Ochrem, B., Małgorzata, G., Waszczuk-Gajda, A., Drozd-Sokolowska, J., Czemerska, M., Paluszewska, M., Zarzycka, E., Masternak, A., Hawrylecka, Dr., Podhoreka, M., Giannopoulos, K., Gromek, T., Oleksiuk, J., Armatys, bA., Helbig, G., Sobas, M., Szczepaniak, A., Rzenno, E., Rodzaj, M., Piatkowska-Jakubas, B., Skret, A., Pluta, A., Barańska, E., Vasconcelos, G., Brioso, J., Nunes, A., Bogalho, I., Espadana, A., Coucelo, M., Marini, S., Azevedo, J., Crisostomo, A.I., Ribeiro, L., Pereira, V., Botelho, A., Mariz, J.M., Guimaraes, J.E., Aguiar, E., Coutinho, J., Noriega, V., García, L., Varela, C., Debén, G., González, M.R., Encinas, M., Bendaña, A., González, S., Bello, J.L., Albors, M., Algarra, L., Romero, J.R., Bermon, J.S., Varo, M.J., López, V., López, E., Mora, C., Amorós, C., Romero, A., Jaramillo, A., Valdez, N., Molina, I., Fernández, A., Sánchez, B., García, A., Castaño, V., López, T., Bernabeu, J., Sánchez, M.J., Fernández, C., Gil, C., Botella, C., Fernández, P., Pacheco, M., Tarín, F., Verdú, J.J., García, M.J., Mellado, A., García, M.C., González, J., Castillo, T., Colado, E., Alonso, S., Recio, I., Cabezudo, M., Davila, J., Rodríguez, M.J., Barez, A., Díaz, B., Prieto, J., Arnan, M., Marín, C., Mansilla, M., Balaberdi, A., Amutio, M.E., del Orbe, R.A., Ancin, I., Ruíz, J.C., Olivalres, M., Gómez, C., gonzález, I., Celis, M., Atutxa, K., Carrascosa, T., Artola, T., Lizuain, M., Rodriguez, J .I., Arce, O., Márquez, J.A., Atuch, J., Marco de Lucas, F., Díez, Z., Dávila, B., Cantalejo, R., Díaz, M., Labrador, J., Serra, F., Hermida, G., Díaz, F.J., de Vicente, P., Álvarez, R., Alonso, C., Bergua, J.M., Ugalde, N., Pardal, E., Saldaña, R., Rodríguez, F., Martín, E., Hermosín, L., Garrastazul, M.P., Marchante, I., Raposo, J.A., Capote, F.J., Colorado, M., Batlle, A., Yañez, L., García, S., González, P., Ocio, E.M., Briz, M., Bermúdez, A., Jiménez, C., Beltrán, S., Montagud, M., Castillo, I., García, R., Gascón, A., Clavel, J., Lancharro, A., Lnares, L., Herráez, M.M., Milena, A., Romero, M.J., Hernández, B., Calle, C., Benegas, R., Bolívar, Dr., Serrano, J., Dorado, F.J., Sánchez, J., Martínez, M.C., Cerveró, C.J., Busto, M.J., Bernal, M., Moratalla, L., Mesa, Z., Jurado, M., De Miguel, D., Santos, A.B., Arbeteta, J., Pérez, E., Caminos, N., Uresandi, N., Argoitiaituart, N., Swen, J., Uranga, A., Olazaba, I., Gainza, E., Romero, P., Gil, E., Palma, A.J., Gómez, K.G., Solé, M., Rodríguez, J.N., Murillo, I.M., Marco, J., Serena, J., Marco, V., Perella, M., Costilla, L., López, J.A., Baena, A., Almagro, P., Hermosilla, M., Esteban, A., Campeny, B.A., Nájera, M.J., Herrra, P., Fernández, R., González, J.D., Torres, L., Jiménez, S., Gómez, M.T., Bilbao, C., Rodríguez, C., Hong, A., Ramos de Laón, Y., Afonso, V., Ramos, F., Fuertes, M., de Cabo, E., Aguilera, C., Megido, M., García, T., Lavilla, E., Varela, M., Ferrero, S., Arias, J., Vizcaya, L., Roldán, A., Vilches, A., Penalva, M.J., Vázquez, J., Calderón, M.T., Matilla, A., Serí, C., Otero, M.J., García, N., Sandoval, E., Franco, C., Flores, R., Bravo, P., López, A., López, J.L., Blas, C., Díez, A., Alonso, J.M., Soto, C., Arenas, A., García, J., Martín, Y., Villafuerte, P.S., Magro, E., Bautista, G., De Laiglesia, A., Rodríguez, G., Solán, L., Chicano, M., Balsalobre, P., Monsalvo, S., Font, P., Carbonell, D., Martínez, C., Humala, K., Kerguelen, A.E., Hernández, D., Gasior, M., Gómez, P., Sánchez, I., Redondo, S., Llorente, L., Bengochea, M., Pérez, J., Sebrango, A., M. santero, Morales, A., Figuera, A., Villafuerte, P., Alegre, A., Fernández, E., Alonso, A., Martínez, M.P., Martínez, J., Cedena, M.T., Moreno, L., De la Fuente, A., García, D., Chamorro, C., Pradillo, V., Martí, E., Sánchez, J.M., Delgado, I., Rosado, B., Velasco, A., Miranda, C., Salvatierra, G., Foncillas, M., Hernández, J.A., Escolano, C., Benabente, C., Martínez, R., Polo, M., Anguita, E., Riaza, R., Amores, G., Requena, M.J., Javier, F., Villaloón, L., Aláez, C., Nistal, S., Navas, B., Andreu, M.A., Herrera, P., López, J., García, M., Moreno, M.J., Queipo, M.P., Hernández, A., Barrios, M., Heiniger, A., Jiménez, A., Contento, A., López, F., Alcalá, M., Lorente, S., González, M., Morales, E.M., Gutierrez, J., Serna, M.J., Beltrán, V., Romera, M., Berenguer, M., MArtínez, A., Tejedor, A., Amigo, M.L., Ortuño, F., Jerez, A., López, O., Moraleda, J.M., Rosique, P., Gómez, J., Garay, M.C., Cerezuela, P., MArtínez, A.B., González, A., Ibáñez, J., Alfaro, M.J., Mateos, M., Goñi, M.A., Araiz, M.A., Gorosquieta, A., Zudaire, M., Viguria, M., Zabala, A., Alvarellos, M., Quispe, I., Sánchez, M.P., Hurtado, G., Pérez, M., Burguete, Y., Areizaga, N., Galicia, T., Rifón, J., Alfonso, A., Prósper, F., Marcos, M., Tamariz, L.E., Riego, V., Manubens, A., Larrayoz, M.J., Calasanz, M.J., Mañú, A., Paiva, B., Vázquez, I., Burgos, L., Pereiro, M., Rodríguez, M., Pastoriza, M.C., Mendez, J.A., Sastre, J.L., Iglesias, M., Ulibarrena, C., Campoy, F., Jaimes, D., Albarrán, B., Solano, J., Silvestre, A., Albo, C., Suarez, S., Loureiro, C., Figueroa, I., Fernández, M.A., Martínez, A., Poderós, C., Vazquez, J., Iglesias, L., Nieto, A., Torrado, T., Martínez, A.M., Amador, M.L., Oubiña, P., Feijó, E., Dios, A., Loyola, I., Roreno, R., Simiele, A., Álvarez, L., Turcu, V., Vidriales, B., Avendaño, A., Chillón, C., González, V., Govantes, J.V., Rubio, S., Tapia, M., Olivier, C., Queizán, J.A., Pérez, O., Vera, J.A., Muñoz, C., rodriguez, A., González, N., Pérez, J.A., Soria, E., I.Espigado, Falantes, J., Montero, I., García, P., Rodríguez, E., Carrillo, E., Caballero, T., García, C., Couto, C., Simón, I., Gómez, M., Aguilar, C., González, B.J., Lakhwani, S., Bienert, A., González, B., Cabello, A., Oliva, A.Y., González, H., Sancho, L., Paricio, M., Perdiguer, L., Solano, F., Lerma, A., Martínez, M.D., Gómez, M.I., Yeguas, A., Montesinos, P., Barragán, E., Sargas, C., Amigo, R., Martinez, D., Boluda, B., Rodríguez, R., Acuña, E., Cano, I., Escrivá, A., Pedreño, M., Navalón, A., Orts, M., Sayas, M.J., Fernández, M.J., Juan, M.L., Gómez, E., Gimeno, M., Donato, E., Cejalvo, M., Tormo, M., Calabuig, M., Navarro, B., Martin, I., Villamont, E., Miralles, A., Lluch, R., Moragues, M., Ruiz, M.A., Benet, C., Valero, M., Linares, M., Collado, R., Orero, M., Ibañez, P., Lis, M.J., Pérez, P.L., Roig, M., López, M., Mena, A.V., Picón, I., Cánovas, V., Palacios, A., Cuello, R., Borrego, J., burgois, M., Cantalapiedra, A., Norberto, O., Angomas, E., Cidoncha, B., Cuevas, L., Robles, D., Mendiazabal, A., Oiartzabal, I., Guinea de Castro, J.M., Montes, C., Carrasco, V., Pérez, A., Moneva, J.J., Olave, M., Bonafonte, E., Mayor, L., Azaceta, G., Palomera, L., Malo, M., Escobar, M.J., Grasa, J.M., De Rueda, B., Aulés, A., Salvador, C., Ansó, V., Iborra, A., Delagado, P., Rubio, A., Stevenazzi, M., Alpire, I., Irigoin, V., Díaz, L., Guillermo, C., Guadagna, R., Grille, S., Oliver, C., Boada, M., Vales, V., Prado, A.I., De los Santos, A.P., Simoes, Catia, Gonzalez, Carmen, Vergez, François, Sarry, Audrey, Bertoli, Sarah, Ariceta, Beñat, Martínez-Cuadrón, David, Bergua, Juan-Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez-Lorenzo, Jose-Luis, Vidriales, Maria-Belen, Chillon, Carmen, Labrador, Jorge, Falantes, Jose-Francisco, Sayas, María-José, Ayala, Rosa, Martinez-Lopez, Joaquin, Villar, Sara, Calasanz, Maria-Jose, Prosper, Felipe, San-Miguel, Jesús F., Sanz, Miguel Á., Récher, Christian, Paiva, Bruno, and Montesinos, Pau
- Published
- 2024
- Full Text
- View/download PDF
7. Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55–65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
- Author
-
Ribera, Josep-Maria, García, Olga, Gil, Cristina, Mercadal, Santiago, García-Cadenas, Irene, Montesinos, Pau, Barba, Pere, Vives, Susana, González-Campos, José, Tormo, Mar, Esteve, Jordi, López, Aurelio, Moreno, María José, Ribera, Jordi, Alonso, Natalia, Bermúdez, Arancha, Amigo, María Luz, Genescà, Eulàlia, García, Daniel, Vall-Llovera, Ferran, Bergua, Juan Miguel, Guàrdia, Ramon, Monteserín, María Carmen, Bernal, Teresa, Calbacho, María, Martínez, María Pilar, and Feliu, Evarist
- Published
- 2018
- Full Text
- View/download PDF
8. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
- Author
-
Stahl, Maximilian, DeVeaux, Michelle, Montesinos, Pau, Itzykson, Raphael, Ritchie, Ellen K., Sekeres, Mikkael A., Barnard, John D., Podoltsev, Nikolai A., Brunner, Andrew M., Komrokji, Rami S., Bhatt, Vijaya R., Al-Kali, Aref, Cluzeau, Thomas, Santini, Valeria, Fathi, Amir T., Roboz, Gail J., Fenaux, Pierre, Litzow, Mark R., Perreault, Sarah, Kim, Tae Kon, Prebet, Thomas, Vey, Norbert, Verma, Vivek, Germing, Ulrich, Bergua, Juan Miguel, Serrano, Josefina, Gore, Steven D., and Zeidan, Amer M.
- Published
- 2018
- Full Text
- View/download PDF
9. AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
- Author
-
Colmenares, Rafael, primary, Sargas, Claudia, additional, Álvarez, Noemí, additional, Chillón, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao-Sieyro, Cristina, additional, de la Torre, Esther Prados, additional, Martínez-Cuadrón, David, additional, Rodríguez-Veiga, Rebeca, additional, Boluda, Blanca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso-Domínguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, María Luz, additional, Herrera-Puente, Pilar, additional, Sayas, María José, additional, Lavilla-Rubira, Esperanza, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Pérez-Simón, José Antonio, additional, Gómez-Casares, María Teresa, additional, Sánchez-García, Joaquín, additional, Barragán, Eva, additional, Martínez-López, Joaquín, additional, and Montesinos, Pau, additional
- Published
- 2023
- Full Text
- View/download PDF
10. POSTER: AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
- Author
-
Colmenares, Rafael, primary, Sargas, Claudia, additional, Álvarez, Noemí, additional, Chillón, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao-Sieyro, Cristina, additional, de la Torre, Esther Prados, additional, Martínez-Cuadrón, David, additional, Rodríguez-Veiga, Rebeca, additional, Boluda, Blanca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso-Domínguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, María Luz, additional, Herrera-Puente, Pilar, additional, Sayas, María José, additional, Lavilla-Rubira, Esperanza, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Pérez-Simón, José Antonio, additional, Gómez-Casares, María Teresa, additional, Sánchez-García, Joaquín, additional, Barragán, Eva, additional, Martínez-López, Joaquín, additional, and Montesinos, Pau, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
- Author
-
Ribera, Josep-Maria, primary, Morgades, Mireia, additional, Garcia-Calduch, Olga, additional, Sirvent, Maialen, additional, Buendia, Buenaventura, additional, Cervera, Marta, additional, Luzardo, Hugo, additional, Hernandez-Rivas, Jesus-Maria, additional, Sitges, Marta, additional, Garcia-Cadenas, Irene, additional, Abrisqueta, Pau, additional, Montesinos, Pau, additional, Bastos-Oreiro, Mariana, additional, De Llano, Maria-Paz Queipo, additional, Bravo, Pilar, additional, Torrent, Anna, additional, Herrera, Pilar, additional, Garcia-Guinon, Antoni, additional, Vall-llovera, Ferran, additional, Serrano, Josefina, additional, Terol, Maria-Jose, additional, Bergua, Juan-Miguel, additional, Garcia-Noblejas, Ana, additional, Barrenetxea, Cristina, additional, Llorente, Laura, additional, Garcia-Belmonte, Daniel, additional, Gimeno, Eva, additional, Cladera, Antonia, additional, Mercadal, Santiago, additional, and Sancho, Juan-Manuel, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
- Author
-
Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal del Castillo, Teresa, Martínez-Sánchez, María del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, and Montesinos, Pau
- Published
- 2021
- Full Text
- View/download PDF
13. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
- Author
-
Sargas, Claudia, Ayala Díaz, Rosa María, Larráyoz, María José, Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao Sieyro, Cristina, Prados de la Torre, Esther, Martínez Cuadrón, David, Rodríguez Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martínez Sánchez, Pilar, Soriano, Elena, Serrano, Josefina, Alonso Domínguez, Juan Manuel, García Boyero, Raimundo, Amigo, Maria Luz, Herrera Puente, Pilar, Sayas, María José, Lavilla Rubira, Esperanza, Martínez López, Joaquín, Calasanz, María José, García Sanz, Ramón, Pérez Simón, José Antonio, Gómez Casares, María Teresa, Sánchez García, Joaquín, Barragán, Eva, Montesinos, Pau, Sargas, Claudia, Ayala Díaz, Rosa María, Larráyoz, María José, Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao Sieyro, Cristina, Prados de la Torre, Esther, Martínez Cuadrón, David, Rodríguez Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martínez Sánchez, Pilar, Soriano, Elena, Serrano, Josefina, Alonso Domínguez, Juan Manuel, García Boyero, Raimundo, Amigo, Maria Luz, Herrera Puente, Pilar, Sayas, María José, Lavilla Rubira, Esperanza, Martínez López, Joaquín, Calasanz, María José, García Sanz, Ramón, Pérez Simón, José Antonio, Gómez Casares, María Teresa, Sánchez García, Joaquín, Barragán, Eva, and Montesinos, Pau
- Abstract
Next–Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross–validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS–AML project; NCT03311815) with standardized NGS of consensus genes (ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 and WT1) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co–occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia–related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies., Bristol-Myers Squibb/Celgene, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Depto. de Medicina, Fac. de Medicina, TRUE, pub
- Published
- 2023
14. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
- Author
-
Villar, Sara, primary, Ariceta, Beñat, additional, Agirre, Xabier, additional, Urribarri, Aura Daniela, additional, Ayala, Rosa, additional, Martínez-Cuadrón, David, additional, Bergua, Juan Miguel, additional, Vives, Susana, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez, Pilar, additional, Serrano, Josefina, additional, Simoes, Catia, additional, Herrera, Pilar, additional, Calasanz, Maria José, additional, Alfonso-Piérola, Ana, additional, Paiva, Bruno, additional, Martínez-López, Joaquín, additional, San Miguel, Jesús F., additional, Prósper, Felipe, additional, and Montesinos, Pau, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile
- Author
-
Knapper, Steven, Chevassut, Timothy, Duarte, Rafael, Bergua, Juan Miguel, Salamero, Olga, Johansen, Malin, Jacobsen, Tove Flem, Hals, Petter-Arnt, Rasch, Wenche, Gianella-Borradori, Athos, and Smith, Matthew
- Published
- 2014
- Full Text
- View/download PDF
16. AML-468 Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: “Real-Life” Data Versus the RATIFY Study
- Author
-
Bobes, Alejandro, Tormo, Mar, Diaz-Beya, Marina, Beneit, Paola, Botella, Carmen, Fernández Moreno, Ainhoa, Mayol, Antonia Sampol, Sangerman, Montserrat Arnan, Bermejo, Ana Yeguas, de la Luz Amigo, Maria, Labrador, Jorge, García Guinon, Antoni, Garrido, Ana, Serrano, Josefina, Polo, Susana Vives, García Fortes, Maria, José Sayas, Maria, Bergua, Juan Miguel, Olave, María Teresa, Vall-Llovera, Ferran, Bargay, Juan, Sanchez, María Pereiro, García Boyero, Raimundo, Diaz-Lopez, Antonio, and de la Fuente, Adolfo
- Published
- 2024
- Full Text
- View/download PDF
17. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
- Author
-
Simoes, Catia, Villar, Sara, Ariceta, Beñat, Garcés, Juan‐José, Burgos, Leire, Alignani, Diego, Sarvide, Sarai, Martínez‐Cuadrón, David, Bergua, Juan‐Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, and Lopez‐Lorenzo, Jose‐Luis
- Subjects
ACUTE myeloid leukemia ,ACUTE promyelocytic leukemia ,SOMATIC mutation - Abstract
In addition to RNAseq, whole-exome sequencing (WES) was performed using molecular barcoding in paired diagnostic-MRD leukaemic cells from 14 patients (6 of them having paired RNAseq and WES data) (Table S1), all of whom achieving CR/MRD+ (Figure 1A). Among the 1346 mutations that either became undetectable or present at MRD, recurrence in 3 or more patients was observed in 48 genes and time points exclusivity were observed in 20 genes (Figure S3). Differential gene expression analysis was performed in I R i using DESeq2 (Methods S1).[12] There was only one gene ( I PIEZO2 i ) differentially expressed between leukaemic cells at diagnosis versus after treatment in patients achieving PR. By contrast, there were 117 differentially expressed genes (adj I p i <0.05, log2FoldChange > |2|) between leukaemic cells at diagnosis vs after treatment in CR/MRD+ patients (Figure S2, Table S2). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
18. Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group
- Author
-
Sargas, Claudia, primary, Ayala, Rosa, additional, Chillon, Carmen, additional, Larrayoz, Maria Jose, additional, Carrillo, Estrella, additional, Bilbao, Cristina, additional, Yébenes, Manuel, additional, Llop, Marta, additional, Rapado, Inmaculada, additional, Garcia-Sanz, Ramon, additional, Vazquez, Iria, additional, Soria, Elena, additional, Sánchez-Sosa, Santiago, additional, Janusz, Kamila, additional, Botella, Carmen, additional, Serrano, Josefina, additional, Martinez-Cuadron, David, additional, Bergua, Juan-Miguel, additional, Amigo, Maria Luz, additional, Martinez Sanchez, Pilar, additional, Tormo, Mar, additional, Bernal, Teresa, additional, Herrera-Puente, Pilar, additional, García-Boyero, Raimundo, additional, Algarra, Lorenzo, additional, Sayas, Maria Jose, additional, Costilla-Barriga, Lisette, additional, Pérez-Santolalla, Esther, additional, Marchante, Inmaculada, additional, Lavilla-Rubira, Esperanza, additional, Noriega, Víctor, additional, Alonso Dominguez, Juan Manuel, additional, Sanz, Miguel A., additional, Sánchez, Joaquín, additional, Gómez-Casares, María Teresa, additional, Perez-Simon, Jose A., additional, Calasanz, María José, additional, González, Marcos, additional, Martínez-López, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries
- Author
-
Recher, Christian, primary, Rollig, Christoph, additional, Berard, Emilie, additional, Bertoli, Sarah, additional, Dumas, Pierre-Yves, additional, Tavitian, Suzanne, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Platzbecker, Uwe, additional, Müller-Tidow, Carsten, additional, Baldus, Claudia D., additional, Martínez-Cuadrón, David, additional, Serrano, Josefina, additional, Martínez, Pilar, additional, Rodríguez-Arbolí, Eduardo, additional, Gil, Cristina, additional, Bergua, Juan-Miguel, additional, Bernal, Teresa, additional, de la Fuente, Adolfo, additional, Delabesse, Eric, additional, Bidet, Audrey, additional, Pigneux, Arnaud, additional, Montesinos, Pau, additional, and Kramer, Michael, additional
- Published
- 2021
- Full Text
- View/download PDF
20. First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.
- Author
-
Belada, David, primary, Kopeckova, Katerina, additional, Bergua, Juan Miguel, additional, André, Marc, additional, Perez Persona, Ernesto, additional, Pichler, Petra, additional, Klöpfer, Pia, additional, Brackertz, Bettina, additional, Lohrmann, Emanuel, additional, Lahiry, Anirban, additional, Shah, Neha, additional, Brugger, Wolfram, additional, Burke, John M., additional, and Nowakowski, Grzegorz S., additional
- Published
- 2021
- Full Text
- View/download PDF
21. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
- Author
-
Nowakowski, Grzegorz S., primary, Chiappella, Annalisa, additional, Gascoyne, Randy D., additional, Scott, David W., additional, Zhang, Qingyuan, additional, Jurczak, Wojciech, additional, Özcan, Muhit, additional, Hong, Xiaonan, additional, Zhu, Jun, additional, Jin, Jie, additional, Belada, David, additional, Bergua, Juan Miguel, additional, Piazza, Francesco, additional, Mócikova, Heidi, additional, Molinari, Anna Lia, additional, Yoon, Dok Hyun, additional, Cavallo, Federica, additional, Tani, Monica, additional, Yamamoto, Kazuhito, additional, Izutsu, Koji, additional, Kato, Koji, additional, Czuczman, Myron, additional, Hersey, Sarah, additional, Kilcoyne, Adrian, additional, Russo, Jacqueline, additional, Hudak, Krista, additional, Zhang, Jingshan, additional, Wade, Steve, additional, Witzig, Thomas E., additional, and Vitolo, Umberto, additional
- Published
- 2021
- Full Text
- View/download PDF
22. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
- Author
-
Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal Del Castillo, Teresa, Martínez-Sánchez, María Del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, Montesinos, Pau, PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Instituto de Salud Carlos III, and Centro de Investigación Biomédica en Red Cáncer (España)
- Subjects
Oncology ,medicine.medical_specialty ,NPM1 ,European LeukemiaNet ,Internal medicine ,CEBPA ,Immunology and Allergy ,Medicine ,Humans ,Transplantation, Homologous ,Cumulative incidence ,Transplantation ,Acute myeloid leukemia ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Cell Biology ,Hematology ,Confidence interval ,Allogeneic stem cell transplant ,Leukemia, Myeloid, Acute ,Autologous stem cell transplant ,Cytogenetic Analysis ,Molecular Medicine ,Stem cell ,business ,Nucleophosmin - Abstract
PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Espa~nol de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD alloSCT should be the preferred postremission strategy in IRmol patients., Supported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/12/00369) and B.V. (CB16/12/00233).
- Published
- 2020
23. NPM1+ /FLT3- Acute Myeloid Leukemia after JAK2-V617F+ Essential Thrombocythemia. Management and Prognosis
- Author
-
Moriano, Baldomero, primary, Barragan, Eva, additional, Ferré, Oscar, additional, Casas, Ignacio, additional, Prieto-Fernandez, Julio, additional, Hernandez, Carmen, additional, Cáceres, Sara, additional, Suárez, Sara, additional, Cardesa, Rocío, additional, Arcos, María José, additional, Bañas, Helena, additional, and Bergua, Juan Miguel, additional
- Published
- 2021
- Full Text
- View/download PDF
24. Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
- Author
-
Simoes, Catia Patricia, primary, Paiva, Bruno, additional, Martínez-Cuadron, David, additional, Bergua, Juan-Miguel, additional, Vives, Susana, additional, Algarra, Jesús Lorenzo, additional, Tormo, Mar, additional, Martinez, Pilar, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Ramos, Fernando, additional, Salamero, Olga, additional, Lavilla, Esperanza, additional, Gil, Cristina, additional, Lopez Lorenzo, Jose Luiz, additional, Vidriales, Maria-Belen, additional, Labrador, Jorge, additional, Falantes, José F., additional, Sayas, Maria Jose, additional, Ayala, Rosa, additional, Martinez-Lopez, Joaquin, additional, Villar, Sara, additional, Calasanz, María José, additional, Prosper, Felipe, additional, San-Miguel, Jesús F., additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional
- Published
- 2020
- Full Text
- View/download PDF
25. Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates
- Author
-
Martinez-Lopez, Joaquin, primary, Montesinos, Pau, additional, Martinez Sanchez, Pilar, additional, Gorrochategui, Julian, additional, Rojas, Jose Luis, additional, Primo, Daniel, additional, Bergua, Juan-Miguel, additional, Ayala, Rosa M M., additional, Calbacho, Maria, additional, López-Muñoz, Nieves, additional, Acuña, Evelyn, additional, Pérez-Simón, Jose Antonio, additional, de la Fuente, Adolfo, additional, Perez De Oteyza, Jaime, additional, Rodríguez-Veiga, Rebeca, additional, Boluda, Blanca, additional, Cano, Isabel, additional, and Ballesteros, Joan, additional
- Published
- 2020
- Full Text
- View/download PDF
26. Hepatitis B Virus Infection
- Author
-
Bergua, Juan Miguel, Cabrera, Carmen, and Bañas, Helena
- Published
- 2009
27. Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
- Author
-
Megías-Vericat, Juan Eduardo, Martínez-Cuadrón, David, López, Joaquín Martínez, Bergua, Juan Miguel, Tormo, Mar, Serrano, Josefina, González, Ataulfo, de Oteyza, Jaime Pérez, Vives Polo, Susana, Vidriales, Belén, Herrera, Pilar, Vera, Juan Antonio, Martínez, Aurelio López, de la Fuente, Adolfo, Amador, Ma Lourdes, Hernández-Rivas, José-Ángel, Fernández, Ma Ángeles, Cerveró, Carlos Javier, Morillo, Daniel, Campo, Pilar Hernández, Gorrochategui, Julián, Primo, Daniel, Rojas, José Luis, Guenova, Margarita, Ballesteros, Joan, Sanz, Miguel, Montesinos, Pau, and Universitat Autònoma de Barcelona
- Subjects
0301 basic medicine ,Anthracycline ,Daunorubicin ,Pharmacology ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Idarubicin ,Potency ,ex-vivo test ,Mitoxantrone ,Acute myeloid leukemia ,business.industry ,lcsh:RC633-647.5 ,Myeloid leukemia ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,Ex-vivo test ,Personalized medicine ,030104 developmental biology ,Infectious Diseases ,030220 oncology & carcinogenesis ,Cytarabine ,Original Article ,business ,Ex vivo ,medicine.drug - Abstract
BACKGROUND: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates. MATERIALS AND METHODS: Using an ex vivo test we have analyzed if a subset of AML patients may respond differently to cytarabine combined with idarubicin, daunorubicin or mitoxantrone. Bone marrow (BM) samples of 198 AML patients were incubated for 48 hours in 96 well plates, each well containing different drugs or drug combinations at different concentrations. Ex vivo drug sensitivity analysis was made using the PharmaFlow platform maintaining the BM microenvironment. Drug response was evaluated as depletion of AML blast cells in each well after incubation. Annexin V-FITC was used to quantify the ability of the drugs to induce apoptosis, and pharmacological responses were calculated using pharmacokinetic population models. RESULTS: Similar dose-respond graphs were generated for the three anthracyclines, with a slight decrease in EC50 with idarubicin (p=1.462E-06), whereas the interpatient variability of either drug was large. To identify those cases of selective sensitivity to anthracyclines, potency was compared, in terms of area under the curve. Differences in anthracycline monotherapy potency greater than 30% from 3 pairwise comparisons were identified in 28.3% of samples. Furthermore, different sensitivity was detected in 8.2% of patients comparing combinations of cytarabine and anthracyclines. DISCUSSION: A third of the patients could benefit of the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed.
- Published
- 2019
28. Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial
- Author
-
Ribera, Josep-Maria, primary, Morgades, Mireia, primary, Ciudad, Juana, primary, Montesinos, Pau, primary, Barba, Pere, primary, García-Cadenas, Irene, primary, Moreno, María José, primary, Vives, Susana, primary, Esteve, Jordi, primary, Gil, Cristina, primary, Monsalvo, Silvia, primary, Artola, María Teresa, primary, Ribera, Jordi, primary, Genescà, Eulàlia, primary, Tormo, Mar, primary, Cervera, Marta, primary, Martínez-Carballeira, Daniel, primary, Novo, Andrés, primary, González-Campos, José, primary, Soria, Beatriz, primary, Bermúdez, Arancha, primary, Martínez, Aurelio López, primary, Mercadal, Santiago, primary, Fernández-Martín, Rosa, primary, Coll, Rosa, primary, Serrano, Josefina, primary, Amigo, Maria Luz, primary, Martínez-Sánchez, Pilar, primary, Bergua, Juan-Miguel, primary, Serrano-Maestro, Alfons, primary, Giménez Conca, Alberto, primary, Barrena, Susana, primary, Granada, Isabel, primary, Feliu, Evarist, primary, and Orfao, Alberto, primary
- Published
- 2019
- Full Text
- View/download PDF
29. Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.
- Author
-
Villaescusa, Teresa, Vázquez, Lourdes, Bergua, Juan Miguel, García, Julio, Romero, Antonio, Olave, M. Teresa, García Belmonte, Daniel, and Queipo de Llano, M. Paz
- Subjects
ANTIFUNGAL agents ,MYCOSES ,ASPERGILLUS ,ECHINOCANDINS ,CANDIDA ,DRUG efficacy ,MEDICATION safety ,DRUG toxicity - Abstract
Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
30. Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols
- Author
-
Genesca, Eulalia, primary, Morgades, Mireia, additional, Montesinos, Pau, additional, Barba, Pere, additional, Gil, Cristina, additional, Guàrdia, Ramon, additional, Moreno, Maria Jose, additional, Martínez-Carballeira, Daniel, additional, García-Cadenas, Irene, additional, Vives, Susana, additional, Ribera, Jordi, additional, González-Campos, José, additional, Diaz-Beyá, Marina, additional, Mercadal, Santiago, additional, Artola, Maria Teresa, additional, Cladera, Antonia, additional, Tormo, Mar, additional, Bermudez, Arancha, additional, Vall-Llovera, Ferran, additional, Martinez, Pilar, additional, Amigo, María-Luz, additional, Bergua, Juan-Miguel, additional, Calbacho, María, additional, Hernández-Rivas, Jesús-María, additional, Monsalvo, Silvia, additional, Novo, Andrés, additional, Cervera, Marta, additional, Garcia-Guiñon, Antonio, additional, Junca, Jordi, additional, Ciudad, Juana, additional, Orfao, Alberto, additional, and Ribera, Josep-Maria, additional
- Published
- 2018
- Full Text
- View/download PDF
31. A Prognostic Index for Patients with Refractory or in First Relapsed Acute Myeloid Leukemia Treated with FLAG-Ida or Flago-Ida
- Author
-
Bergua, Juan Miguel, primary, Montesinos, Pau, additional, Martinez-Cuadrón, David, additional, Fernández-Abellán, Pascual, additional, Serrano, Josefina, additional, Sayas, María José, additional, Prieto-Fernandez, Julio, additional, Garcia, Raimundo, additional, Garcia-Huerta, Ana Julia, additional, Barrios, Manuel, additional, Pérez-López, Cristina, additional, Perez-Encinas, Manuel, additional, Siemele, Adriana, additional, Rodriguez-Macias, Gabriela, additional, Herrera-Puente, Pilar, additional, Rodríguez-Veiga, Rebeca, additional, Martinez-Sanchez, Maria Pilar, additional, Amador-Barciela, Maria Lourdes, additional, and Sanz, Miguel A., additional
- Published
- 2014
- Full Text
- View/download PDF
32. Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse
- Author
-
Alegre, Adrian, primary, Gironella, Merche, additional, Bergua, Juan Miguel, additional, Gonzalez, Esther, additional, Escalante, Fernando, additional, Soler, Alfon, additional, Sampol, Antonia, additional, Gonzalez, Ana Pilar, additional, Cabañas, Valentin, additional, Lahuerta, Juan Jose, additional, Lopez, Aurelio, additional, Dios, Ana, additional, Bárez, Abelardo, additional, Ruiz, Antonio, additional, Vilanova, David, additional, and Díaz-Mediavilla, Joaquín, additional
- Published
- 2014
- Full Text
- View/download PDF
33. Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalisis from the Alma Study
- Author
-
Falantes, Jose, primary, Deben, Guillermo, additional, Martinez Robles, Violeta, additional, Bargay, Joan, additional, Salamero, Olga, additional, Pedro, Carmen, additional, Redondo, Santiago, additional, Garrido, Ana, additional, Bergua, Juan Miguel, additional, Tormo, Mar, additional, Xicoy, Blanca, additional, Font, Patricia, additional, González-López, Tomás José, additional, and Ramos, Fernando, additional
- Published
- 2014
- Full Text
- View/download PDF
34. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
- Author
-
Rosiñol, Laura, Pérez-Simón, José Antonio, Sureda, Anna, de la Rubia, Javier, de Arriba, Felipe, Lahuerta, Juan José, González, José David, Díaz-Mediavilla, Joaquín, Hernández, Belén, García-Frade, Javier, Carrera, Dolores, León, Angel, Hernández, Miguel, Abellán, Pascual Fernández, Bergua, Juan Miguel, San Miguel, Jesús, and Bladé, Joan
- Published
- 2008
- Full Text
- View/download PDF
35. The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
- Author
-
Ayala, Rosa, Rapado, Inmaculada, Onecha, Esther, Martínez-Cuadrón, David, Carreño-Tarragona, Gonzalo, Bergua, Juan Miguel, Vives, Susana, Algarra, Jesus Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, López Lorenzo, Jose Luis, Vidriales, María Belén, Labrador, Jorge, and Falantes, José Francisco
- Subjects
THERAPEUTIC use of antineoplastic agents ,BIOMARKERS ,GENETIC mutation ,SEQUENCE analysis ,CONFIDENCE intervals ,MULTIVARIATE analysis ,NUCLEAR proteins ,ACUTE myeloid leukemia ,TREATMENT effectiveness ,AZACITIDINE ,FLUDARABINE ,CANCER patients ,GENE expression profiling ,SURVIVAL analysis (Biometry) ,GENOMES ,CYTARABINE ,ODDS ratio ,OLD age - Abstract
Simple Summary: Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low–intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10
−7 ) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low–intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
36. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
- Author
-
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, and Sancho JM
- Subjects
- Humans, Young Adult, Aged, Middle Aged, Drug Tapering, Feasibility Studies, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Rituximab therapeutic use, Burkitt Lymphoma drug therapy, Burkitt Lymphoma pathology, Leukemia drug therapy, HIV Infections drug therapy
- Abstract
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks of immunochemotherapy according to stage (localized: 1 and 2 non-bulky; advanced: 2 bulky, 3, 4) and age, with dose reduction in patients >55 years old. Dose-intensity of chemotherapy was reduced in patients ≤55 years old after achieving complete metabolic response (CMR). Their outcomes were compared with those of similar patients included in the former BURKIMAB08 trial, in which there was no dose reduction. CMR was attained in 86 of 107 (80%) patients (17/19 in localized stages and 69/88 in advanced stages). Patients from the BURKIMAB14 trial ≤55 years old showed similar overall survival (OS), fewer infections and cytopenias than patients from the BURKIMAB08 trial. Patients >55 years old had a significantly higher treatment- related mortality despite dose reduction of chemotherapy. With a median follow-up of 3.61 years the 4-year OS probability was 73% (range, 63-81%). Age (≤55 vs. >55 years) and stage (localized vs. advanced) had prognostic significance. No significant differences in OS were observed in HIV-positive versus HIV-negative patients. The results of BURKIMAB14 are similar to those of other dose-intensive immunochemotherapy trials. Age >55 years and advanced stage, but not HIV infection, were associated with poor survival. Dose reduction of chemotherapy in young adults in CMR is safe and does not impact outcomes (clinicaltrials gov. Identifier: NCT05049473).
- Published
- 2024
- Full Text
- View/download PDF
37. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
- Author
-
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Domínguez JM, García-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez-Casares MT, Sánchez-García J, Barragán E, Montesinos P, and On Behalf Of Pethema Group
- Abstract
Next-Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross-validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS-AML project; NCT03311815) with standardized NGS of consensus genes ( ABL1 , ASXL1 , BRAF , CALR , CBL , CEBPA , CSF3R , DNMT3A , ETV6 , EZH2 , FLT3 , GATA2 , HRAS , IDH1 , IDH2 , JAK2 , KIT , KRAS , MPL , NPM1 , NRAS , PTPN11 , RUNX1 , SETBP1 , SF3B1 , SRSF2 , TET2 , TP53 , U2AF1 and WT1 ) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co-occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia-related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies.
- Published
- 2023
- Full Text
- View/download PDF
38. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
- Author
-
Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, López-Pavía M, Trigo F, Martínez-Sánchez MP, Rodríguez-Gutiérrez JI, Rodríguez-Medina C, Gil C, Belmonte DG, Vives S, Foncillas MÁ, Pérez-Encinas M, Novo A, Recio I, Rodríguez-Macías G, Bergua JM, Noriega V, Lavilla E, Roldán-Pérez A, Sanz MA, Montesinos P, and On Behalf Of Pethema Group
- Abstract
The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, there are little direct comparative data on AZA and DEC. This multicenter retrospective study compared the outcomes of AZA and DEC in terms of response and overall survival (OS). Potential predictors associated with response and OS were also evaluated. A total of 626 AML patients were included (487 treated with AZA and 139 with DEC). Response rates were similar in both groups: CR was 18% with AZA vs. 23% with DEC (p = 0.20), CR/CRi was 20.5% vs. 25% (p = 0.27) and ORR was 32% vs. 39.5% (p = 0.12), respectively. Patients with leukocytes < 10 × 109/L, bone marrow blasts < 50% and ECOG ≥ 2 had higher ORR with DEC than with AZA. OS was similar in both groups: 10.4 months (95% CI: 9.2−11.7) vs. 8.8 months (95% CI: 6.7−11.0, p = 0.455), for AZA and DEC, respectively. Age (≥80 years), leukocytes (≥ 10 × 109/L), platelet count (<20 × 109/L) and eGFR (≥45 mL/min/1.73 m2) were associated with higher OS with AZA compared to DEC. In conclusion, we found no differences in response and OS rates in AML patients treated with AZA or DEC.
- Published
- 2022
- Full Text
- View/download PDF
39. Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.
- Author
-
Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, and Montesinos P
- Abstract
Background: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates., Materials and Methods: Using an ex vivo test we have analyzed if a subset of AML patients may respond differently to cytarabine combined with idarubicin, daunorubicin or mitoxantrone. Bone marrow (BM) samples of 198 AML patients were incubated for 48 hours in 96 well plates, each well containing different drugs or drug combinations at different concentrations. Ex vivo drug sensitivity analysis was made using the PharmaFlow platform maintaining the BM microenvironment. Drug response was evaluated as depletion of AML blast cells in each well after incubation. Annexin V-FITC was used to quantify the ability of the drugs to induce apoptosis, and pharmacological responses were calculated using pharmacokinetic population models., Results: Similar dose-respond graphs were generated for the three anthracyclines, with a slight decrease in EC
50 with idarubicin (p=1.462E-06), whereas the interpatient variability of either drug was large. To identify those cases of selective sensitivity to anthracyclines, potency was compared, in terms of area under the curve. Differences in anthracycline monotherapy potency greater than 30% from 3 pairwise comparisons were identified in 28.3% of samples. Furthermore, different sensitivity was detected in 8.2% of patients comparing combinations of cytarabine and anthracyclines., Discussion: A third of the patients could benefit from the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed., Competing Interests: Competing interests: The authors have declared that no competing interests exist.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.